The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | ALPHA3 study: first-line cema-cel consolidation for MRD-positive LBCL after standard therapy
John Burke, MD, Rocky Mountain Cancer Centers, Aurora, CO, shares an overview of the ongoing Phase II ALPHA3 study (NCT06500273) evaluating first-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) who have detectable measurable residual disease (MRD) by circulating tumor DNA (ctDNA) after standard frontline treatment. The study aims to improve event-free survival (EFS) by intervening before clinical relapse. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
